loading
Precedente Chiudi:
$6.08
Aprire:
$6.12
Volume 24 ore:
485.06K
Relative Volume:
0.72
Capitalizzazione di mercato:
$387.94M
Reddito:
-
Utile/perdita netta:
$-36.95M
Rapporto P/E:
-6.6033
EPS:
-0.92
Flusso di cassa netto:
$-33.46M
1 W Prestazione:
-19.46%
1M Prestazione:
-19.03%
6M Prestazione:
-22.72%
1 anno Prestazione:
+97.96%
Intervallo 1D:
Value
$5.68
$6.29
Intervallo di 1 settimana:
Value
$5.68
$7.615
Portata 52W:
Value
$3.09
$13.68

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name
Nome
Larimar Therapeutics Inc
Name
Telefono
844-511-9056
Name
Indirizzo
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Name
Dipendente
42
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
LRMR's Discussions on Twitter

Confronta LRMR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
LRMR 6.08 387.94M 0 -36.95M -33.46M -0.92
VRTX 449.64 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.66 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 588.46 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.13 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.53 24.89B 3.30B -501.07M 1.03B 11.54

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-10-19 Iniziato Guggenheim Buy
2022-02-15 Downgrade William Blair Outperform → Mkt Perform
2021-02-10 Iniziato JMP Securities Mkt Outperform
2021-02-01 Iniziato William Blair Outperform

Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie

pulisher
01:00 AM

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MyChesCo

01:00 AM
pulisher
Nov 20, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Larimar Therapeutics (NASDAQ:LRMR) Given Outperform Rating at William Blair - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics Presents Additional Data from Phase 1 - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Reports Promising Clinical Data for Friedreich's Ataxia Treatment Nomlabofusp | LRMR Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from Analysts - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

(LRMR) Trading Signals - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 16, 2024

Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey

Nov 16, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeu - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey

Nov 14, 2024
pulisher
Nov 14, 2024

Janus Henderson's Strategic Acquisition in Larimar Therapeutics - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Verition Fund Management LLC Reduces Stake in Larimar Therapeuti - GuruFocus.com

Nov 14, 2024
pulisher
Nov 11, 2024

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart

Nov 11, 2024
pulisher
Nov 08, 2024

PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online

Nov 08, 2024
pulisher
Nov 06, 2024

Goldman Sachs Group Inc's Strategic Acquisition in Larimar Thera - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

When (LRMR) Moves Investors should Listen - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 04, 2024

What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World

Nov 02, 2024
pulisher
Nov 02, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics' (LRMR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics Q3 2024 Financial Update - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Larimar: Q3 Earnings Snapshot - CTPost

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics (NASDAQ:LRMR) Shares Gap UpHere's Why - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Oct 30, 2024
pulisher
Oct 26, 2024

(LRMR) Investment Analysis and Advice - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 24, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8%Here's Why - MarketBeat

Oct 24, 2024
pulisher
Oct 20, 2024

Larimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Oppenheimer - Defense World

Oct 20, 2024
pulisher
Oct 17, 2024

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Larimar initiated with bullish view at Oppenheimer on lead drug - MSN

Oct 16, 2024
pulisher
Oct 16, 2024

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga

Oct 16, 2024
pulisher
Oct 16, 2024

Larimar stock gets bullish view at Oppenheimer (LRMR:NASDAQ) - Seeking Alpha

Oct 16, 2024
pulisher
Oct 16, 2024

Oppenheimer Begins Coverage on Larimar Therapeutics (NASDAQ:LRMR) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

(LRMR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 10, 2024

Millennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Larimar Therapeutics Inc (LRMR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

An Analysis of Larimar Therapeutics Inc (LRMR)’s Potential Price Growth - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Larimar Therapeutics Inc (LRMR) Stock: A Year of Highs and Lows - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Hopeful Week For Insiders Who Bought US$540.7k Of Larimar Therapeutics Stock - Simply Wall St

Oct 09, 2024
pulisher
Oct 07, 2024

Technical analysis of Larimar Therapeutics Inc (LRMR) stock chart patterns - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Financial Metrics Unveiled: Larimar Therapeutics Inc (LRMR)’s Key Ratios in the Spotlight - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

Analysts Offer Predictions for Larimar Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:LRMR) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential - Seeking Alpha

Oct 06, 2024
pulisher
Oct 04, 2024

How To Trade (LRMR) - Stock Traders Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Larimar Therapeutics Inc [LRMR] Shares Rise 3.66 % on Thursday - Knox Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Quarry LP Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Oct 04, 2024

Larimar Therapeutics Inc Azioni (LRMR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Larimar Therapeutics Inc Azioni (LRMR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Flynn James E
Director
Feb 16 '24
Buy
8.74
4,290,617
37,499,993
6,151,406
THOMAS FRANK E
Director
Feb 14 '24
Buy
11.00
2,000
22,000
2,000
Shankar Gopi
Chief Development Officer
Dec 07 '23
Buy
3.73
5,000
18,662
5,000
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):